Seattle Genetics: Annual Report 2014 (Seattle Genetics, Inc) - Mar 28, 2015 - Anticipated patent expiry of related ADC technology in US and Europe in between 2027 and 2030; Anticipated patent term extension for certain methods of treatment using SGN-CD33A in US and Europe until 2033
Anticipated patent expiry • Acute Myelogenous Leukemia
|